 | This articlecontainspromotional content. Please helpimprove it by removingpromotional language and inappropriateexternal links, and by adding encyclopedic text written from aneutral point of view.(June 2023) (Learn how and when to remove this message) |
 | |
| Company type | Public |
|---|---|
| ISIN | US40637H1095 |
| Industry | |
| Founded | 1998; 27 years ago (1998) |
| Headquarters | San Diego, California, US |
Area served | Worldwide |
Key people | Helen Torley (president,CEO) |
| Revenue |  US$288 million (2019)[1] |
Number of employees | 136 (February 17, 2021) |
| Website | www |
Halozyme Therapeutics, Inc. is an Americanbiotechnology company. It developsoncology therapies designed to target thetumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered inSan Diego, California.[2]
Halozyme's business is primarily focused on its proprietary and patented recombinant humanhyaluronidase enzyme, rHuPH20.[2] The company's development pipeline is concentrated in clinical stage and pre-clinical stage oncology products, including its proprietary investigational drug, PEGPH20, a pegylated version of rHuPH20, which targetshyaluronan (HA) hightumors. The company is in various phases ofclinical trials with PEGPH20 across multiple solid tumor types, includingpancreatic cancer,non-small cell lung cancer (NSCLC), andgastric cancer, to test the drug's safety and efficacy.[3] Halozyme has oneFDA approved product (Hylenex recombinant, hyaluronidase human injection[4][5]). The company also licenses its drug delivery technology Enhanze[6] to other biopharmaceutical companies, includingRoche,Baxalta,Pfizer,Janssen,AbbVie,Bristol Myers Squibb andLilly.[3]
Since January 2014, Helen Torley has been Chief Executive Officer and President of Halozyme.
Hylenex: Approved by theU.S. Food and Drug Administration (FDA) on 12/02/2005.[4] Hylenex is ahyaluronidase (human recombinant) injection indicated for use insubcutaneous fluid administration, dispersion and absorption of injected drugs, and subcutaneousurography.[7]
Enhanze: Uses recombinant human hyaluronidase to degrade HA and aids in the absorption and dispersion of co-administered injected drugs. Halozyme licenses its Enhanze drug delivery platform technology to other biopharmaceutical companies to enable intravenous to subcutaneous administration conversion and dose optimization.[8]
PEGPH20: APEGylated drug candidate based on Halozyme's proprietary rHuPH20 enzyme (a recombinant human hyaluronidase enzyme).[9] It breaks down or depletes hyaluronan (HA),[10] which can build up in certain tumors. The goal of PEGPH20 is to break down HA so that some anti-cancer therapies and activated immune cells can better reach the cancer cells of HA-high tumors.[3][11] On November 4, 2019, Halozyme announced it has halted development of PEGPH20.[12]
PEG-ADA2: An engineered human recombinant enzyme, adenosine deaminase 2, for decreasing the concentration of immune-suppressiveadenosine in the tumor microenvironment, and PEGylated to prolong its circulation in the body. It has been tested in colon, lung, and pancreatic cancer models in preclinical studies.[13]
HTI-1511 Anti-EGFR ADC: Anantibody-drug conjugate (ADC) with a strongcytotoxin, monomethyl auristatin E, designed to treat EGFR-positive tumors, including those withKRAS andBRAF mutations. It has been tested in colon, lung, andcholangiocarcinoma models in preclinical studies.[13]
Halozyme has many ongoing and completed clinical trials testing the safety and efficacy of its primary investigational drug, PEGPH20, in combination with other therapies, with the goal of finding new treatments for pancreatic cancer, NSCLC, gastric cancer,breast cancer, and others.[2] As of October 2016, the company was sponsoring or collaborating on several clinical trials that were recruiting patients, including: